US FDA grants breakthrough therapy designation to Belite Bio's Tinlarebant for treatment of Stargardt disease
Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced that the US Food and Drug Administration (FDA …